Shares of Pfizer Inc. PFE rallied 1.71% to $25.58 Wednesday, on what proved to be an all-around poor trading session for the ...
The current consensus expectation (according to Wall Street firm CFRA) is that the S&P 500's EPS in 2026 will be 14.1% higher ...
Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...
Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...
Walmart will replace British drugmaker AstraZeneca in the Nasdaq-100 Index on January 20, the exchange operator said on ...
While I believe Pfizer will rebound eventually, it will take some time to do so, and it may not occur in 2026. In the ...
The vaccines subsector received a big fillip from Covid, but its potential extends far beyond combating pandemics. Dr Mike ...
Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...
After the Trump administration announced sweeping changes to the US childhood vaccine schedule this week, parents and ...
The article " These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever " first appeared on MarketBeat.
Zacks Investment Research on MSN
Pfizer Inc. (PFE) is attracting investor attention: Here is what you should know
Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback